NGVT Ingevity Corp

FY2025 10-K
Filed: Feb 26, 2026
Health Care
Chemicals & Allied ProductsSEC EDGAR

Ingevity Corp (NGVT) filed its fiscal year 2025 10-K annual report with the SEC on Feb 26, 2026. This page provides AI-powered analysis of the filing, including business overview, management discussion, risk factors, and key financial metrics from XBRL data.

AI Filing Analysis
FY2025 10-K

Business Overview

  • Core business: Specialty chemicals and materials manufacturing, focusing on automotive carbon, pavement, and road marking technologies
  • Legal expense accrual of $95.4M for patent infringement judgment against BASF, final appeal lost in Feb 2026, impacting financials and cash flow
+3 more insights

Risk Factors

  • Regulatory risk: EU GDPR, CCPA, and China Cybersecurity Law impose complex data privacy compliance and significant fines for violations
  • Geopolitical risk: 43% sales outside US exposed to tariffs and retaliatory measures by China harming Performance Materials and Chemicals margins
+3 more insights

Financial Summary
XBRL

Revenue

$1.2B

Net Income

-$167M

Gross Margin

39.5%

Operating Margin

35.9%

Net Margin

-14.3%

ROE

-562.6%

Total Assets

$1.7B

EPS (Diluted)

$-4.61

Operating Cash Flow

$331M

Source: XBRL data from Ingevity Corp FY2025 10-K filing on SEC EDGAR. All figures in USD.

Get deeper insights on Ingevity Corp

Access full AI analysis, insider trading data, fund holdings, and cross-signal detection on SignalX.

Try Pro free for 1 month!

Enter SX-8KKYTN at checkout

Limited spots available